JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

JNJ

227.67

+0.26%↑

UNH

368.01

-0.17%↓

TMO

462.97

-1.78%↓

ISRG

450.15

-2.97%↓

ABT

91.92

-1.86%↓

Начало・Списък с акции・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

73.64 3.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

70.72

Максимум

74.29

Ключови измерители
By Trading Economics
Приходи	-100M -229M
Продажби	46M 203M
Марж на печалбата	-112.808
Служители	1,402
EBITDA	4.7B 4.6B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+43.35% upside

Дивиденти
By Dow Jones
Следващи печалби	29.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.8B 12B
Предишно отваряне	70.42
Предишно затваряне	73.64

Настроения в новините

By Acuity

50%

177 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

29.78 / 33.645 Подкрепа & съпротива

Ionis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2026 г., 23:33 ч. UTC

Горещи акции

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28.04.2026 г., 23:24 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28.04.2026 г., 22:46 ч. UTC

Печалби

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28.04.2026 г., 22:37 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28.04.2026 г., 22:15 ч. UTC

Печалби

Значими събития в новините

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28.04.2026 г., 23:19 ч. UTC

Пазарно говорене

Печалби

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28.04.2026 г., 23:09 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees One Rate Rise to 4% in Benign Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28.04.2026 г., 22:51 ч. UTC

Печалби

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28.04.2026 г., 22:40 ч. UTC

Пазарно говорене

Значими събития в новините

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28.04.2026 г., 22:32 ч. UTC

Печалби

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28.04.2026 г., 22:22 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28.04.2026 г., 22:07 ч. UTC

Пазарно говорене

Значими събития в новините

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ionis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

43.35% нагоре

12-месечна прогноза

Среден 103.54 USD 43.35%

Висок 130 USD

Нисък 72 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Ionis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Ionis Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

29.78 / 33.645Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Настроение

By Acuity

177 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.